Clinical trials: Interstitial Lung Diseases
Idiopathic Pulmonary Fibrosis, Familial Pulmonary Fibrosis
Role of Genetics in Idiopathic Pulmonary Fibrosis (IPF)
The purpose of this study is to investigate inherited genetic factors that play a role in the development of familial pulmonary fibrosis and to identify a group of genes that predispose individuals to develop pulmonary fibrosis.
- Conditions
- Idiopathic Pulmonary Fibrosis, Familial Pulmonary Fibrosis, Idiopathic Interstitial Pneumonia, Familial Interstitial Pneumonia
- Trial name
- GWAS (NCT01088217)
- Where
- 4 sites in United States, Iceland
- Volunteers
- 8,000 people
- Sponsor
- National Jewish Health
Healthy Subjects, Chronic Obstructive Pulmonary Disease
Multicenter Study of Impulse Oscillometry in Chinese
The purpose of this study is to establish the reference values of impulse oscillometry (IOS) in healthy Chinese, and compare the indices of IOS in patients with lung disease, such as chronic obstructive pulmonary disease (COPD)…
- Conditions
- Healthy Subjects, Chronic Obstructive Pulmonary Disease, Asthma, Interstitial Lung Disease
- Trial name
- NCT03467880
- Testing
- Clinical Observation
- Where
- 2 sites in China
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- Guangzhou Institute of Respiratory Disease
Interstitial Lung Disease, COPD
Global Utilization And Registry Database for Improved preservAtion of doNor LUNGs
The objective of this registry is to collect and evaluate various clinical effectiveness parameters in patients with transplanted donor lung that were preserved and transported within the LUNGguard system, as well as…
- Conditions
- Interstitial Lung Disease, COPD, Cystic Fibrosis, Pulmonary Fibrosis
- Trial name
- GUARDIANLUNG (NCT04930289)
- Testing
- LungGuard, BAROGuard
- Where
- 15 sites in United States, Belgium
- Volunteers
- 3,500 people
- Sponsor
- Paragonix Technologies
Idiopathic Pulmonary Fibrosis
Safety and Efficacy of Venetoclax in Idiopathic Pulmonary Fibrosis
Based on preclinical data, investigators hypothesize that apoptosis resistance in monocyte-derived macrophages (MDMs) have a decisive role in the development of idiopathic pulmonary fibrosis (IPF).
- Trial name
- NCT05976217
- Testing
- Venetoclax
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- University of Alabama at Birmingham
Pulmonary Disease, Chronic Obstructive, Idiopathic Pulmonary Fibrosis
Respiratory Rate Validation Study - HiCardi+ Wearable Patch Device, Mezoo Co., Ltd.
The purpose of this study is to analyze the accuracy of respiratory and breathing patterns generated through impedance changes generated by a patch-type electrocardiogram device (HiCardi+ wearable patch device, Mezoo Co., Ltd.)…
- Conditions
- Pulmonary Disease, Chronic Obstructive, Idiopathic Pulmonary Fibrosis, Asthma
- Trial name
- NCT05863091
- Testing
- HiCardi+
- Where
- South Korea
- Volunteers
- 211 people
- Sponsor
- Yonsei University
Pulmonary Hypertension, Interstitial Lung Disease
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
The primary objective of this study is to evaluate the effect of 24-weeks of once daily treatment with TPIP versus placebo on exercise capacity in adults with PH-ILD.
- Trial name
- PALM-ILD (NCT07179380)
- Testing
- Treprostinil Palmitil Inhalation Powder
- Where
- 186 sites in United States, Argentina and 28 more
- Volunteers
- 344 people
- Sponsor
- Insmed Incorporated
Interstitial Lung Disease
Virtual Exercise Program in Interstitial Lung Disease (ILD) Patients
Design: this pilot-study uses a two-group random assignment pretest-posttest design. Once the groups are being selected an envelope will be mailed to the participant with the printed version of the exercise program and surveys, a…
- Trial name
- NCT04946708
- Testing
- Exercise program (virtual/remote)
- Where
- Canada
- Volunteers
- 14 people
- Sponsor
- University of Manitoba
Idiopathic Pulmonary Fibrosis
Clinical Efficacy and Safety of Autologous Lung Stem Cell Transplantation in Patients With Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis (IPF) is a chronic and ultimately fatal disease characterized by a progressive damage of lung structure and decline in lung function.This study intends to carry out an open, single-center…
- Trial name
- NCT02745184
- Testing
- Lung stem cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Shanghai East Hospital
Pulmonary Fibrosis
Roll Over Study From 1199.30 BIBF 1120 in Idiopathic Pulmonary Fibrosis (IPF)
The aim of this trial is to offer continuation of BIBF 1120 treatment for patients with Idiopathic Pulmonary Fibrosis (IPF) who have completed a prior clinical trial with that drug.
- Trial name
- NCT01170065
- Testing
- BIBF 1120
- Where
- 57 sites in Argentina, Australia and 19 more
- Volunteers
- 198 people
- Sponsor
- Boehringer Ingelheim
Sarcoidosis, Pulmonary
Hydroxychloroquine as a Steroid-sparing Agent in Extrapulmonary Sarcoidosis
Sarcoidosis is a systemic granulomatous disease of unknown aetiology, mainly affecting the lungs and lymphatics. It affects people worldwide (incidence, 4.7-64/100000; prevalence, 1-36/100000/year).
- Trial name
- CAESAR (NCT05841758)
- Testing
- Hydroxychloroquine
- Where
- 21 sites in France
- Volunteers
- 140 people
- Sponsor
- Hospices Civils de Lyon
Idiopathic Pulmonary Fibrosis
PROOF-Registry New and Extended Belgium -Luxembourg
A Prospective Observational Registry to describe the disease course and outcomes of Idiopathic Pulmonary Fibrosis patients in a real-world clinical setting.
- Trial name
- PROOF-NEXT (NCT03732859)
- Where
- 9 sites in Belgium, Luxembourg
- Volunteers
- 575 people
- Sponsor
- Belgian Thoracic Society
Pulmonary Fibrosis
SVF for Treating Pulmonary Fibrosis Post COVID-19
General description of the study This is a prospective, multicenter, expanded access interventional study of subjects recovered from COVID-19 pneumonia to assess their response to intravenous administration of adipose-derived…
- Trial name
- SVFCOVID-19 (NCT06304623)
- Testing
- Autologous adipose-derived SVF IV administration
- Where
- 2 sites in Nicaragua
- Volunteers
- 40 people
- Sponsor
- Michael H Carstens
Healthy Participants
A Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of AZD8965 in Healthy Participants (Including Japanese and Chinese Participants) and an Open-label Cohort to Assess the Effect of Food on the Pharmacokinetics of AZD8965 in Healthy Participants
The purpose of this study is to assess the safety, tolerability, and pharmacokinetics (PK) of AZD8965 via single and multiple ascending doses in healthy participants (including Japanese and Chinese participants), and to assess…
- Trial name
- NCT06502379
- Testing
- AZD8965
- Where
- United States
- Volunteers
- 147 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Idiopathic Pulmonary Fibrosis
Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of Rentosertib (INS018_055) administered orally in Patients with Idiopathic Pulmonary Fibrosis.
- Trial name
- NCT07687459
- Testing
- INS018_055 tablets
- Where
- 47 sites in China
- Volunteers
- 320 people
- Sponsor
- InSilico Medicine Hong Kong Limited
Idiopathic Pulmonary Fibrosis
Current Status of Diagnosis, Treatment and Quality of Life for Patients with Idiopathic Pulmonary Fibrosis
The goal of this observational study is to explore current status of diagnosis, treatment and quality of life for patients with idiopathic pulmonary fibrosis.
- Trial name
- IPFLife (NCT06629623)
- Testing
- No intervention
- Where
- China
- Volunteers
- 310 people, healthy volunteers welcome
- Sponsor
- Chu Hongling
Idiopathic Pulmonary Fibrosis
Jin-shui Huan-xian Granule in the Treatment of IPF
This study is to evaluate the efficacy and safety of Jin-shui Huan-xian granule for idiopathic pulmonary fibrosis (IPF), establish the treatment scheme, and obtain the high quality clinical evidences.
- Trial name
- NCT04187690
- Testing
- Jin-shui Huan-xian granule
- Where
- China
- Volunteers
- 312 people
- Sponsor
- Henan University of Traditional Chinese Medicine
Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis
To Evaluate the Use of Radiomics to Classify Between Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease
To investigate the ability of machine learning models based on radiomic features extracted from thin-section CT images to differentiate IPF patients from non-IPF interstitial lung diseases.
- Conditions
- Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis, Usual Interstitial Pneumonia
- Trial name
- NCT04430491
- Testing
- radiomics
- Where
- Netherlands
- Volunteers
- 300 people
- Sponsor
- Maastricht University
Rapid Progressive Interstitial Lung Diseases
The Efficacy and Safety of Tocilizumab for Severe RP-ILD Secondary to Systemic Diseases
There is no confirmed drug therapy for RP-ILD. Prognosis is poor of regular treatment. The study is designed to compare efficacy and safety of tocilizumab versus regular treatment in participants with severe RP-ILD secondary to…
- Trial name
- NCT05181397
- Testing
- Tocilizumab
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Peking Union Medical College Hospital
Idiopathic Pulmonary Fibrosis
Metformin to Attenuate Progressive Respiratory Decline in Idiopathic Pulmonary Fibrosis
This is a randomized, placebo-controlled trial of metformin in 400 participants with idiopathic pulmonary fibrosis (IPF) who are at high risk of adverse clinical outcomes based on a proteomic classifier.
- Trial name
- MAVRIC (NCT07520110)
- Testing
- Metformin
- Where
- 15 sites in United States
- Volunteers
- 800 people
- Sponsor
- University of Massachusetts, Worcester
Interstitial Lung Disease With Systemic Sclerosis
Pelvic Floor Dysfunction in Pulmonary Systemic Sclerosis
Systemic sclerosis (SSc) is a heterogeneous multisystem disease characterized by vascular dysfunction, immune abnormalities, and progressive fibrosis of the skin and internal organs.
- Trial name
- NCT07817160
- Testing
- Pelvic Floor Health Knowledge Assessment, Pelvic Floor Dysfunction Assessment, Core Endurance Assessment
- Where
- Turkey (Türkiye)
- Volunteers
- 37 people
- Sponsor
- Biruni University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.